Your Guide to Mastering CMC Regulatory Success in Biotherapeutics: A Must-Watch Webinar
Elevate your understanding of biotherapeutics including cell and gene therapies with Veristat's regulatory CMC experts. Dive deep into manufacturing,...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
Successfully transitioning from academic or bench-top production to manufacture clinical-grade material is not an easy feat. There are many factors new sponsors must consider when determining readiness to file an Investigational New Drug (IND) from a manufacturing perspective. FDA guidance for INDs for Phase 1 points out that ‘insufficient data to make an evaluation of safety is the only basis of a clinical hold based on the CMC section.’
Listen to the full episode on Veristat’s Advancing Revolutionary Therapies (ART) Podcast to learn more about the key CMC fundamentals and pitfalls of preparing for an IND.
Meet Veristat. Learn More: Regulatory Affairs, Operations and Consulting
Elevate your understanding of biotherapeutics including cell and gene therapies with Veristat's regulatory CMC experts. Dive deep into manufacturing,...
Delve into the critical steps for Structure-Data (SD) File preparation for FDA regulatory submissions. Learn how Veristat can ensure your submission...
Stay updated with Veristat's January 2025 FDA guidance and regulatory news, including new drug approvals, draft guidances, and regulatory updates...